UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 scPharmaceuticals Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) 25 Mall Road, Suite 203 Burlington, Massachusetts 01803 (Address of principal executive offices) (Zip Code) (Commission File Number) Delaware 001-38293 4 ...

Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023 BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: S ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Anupam Leesy - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals' Third Quarter 2024 E ...

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -23.33%. A quarter ago, it was expected that this company would post a loss of $0.44 per share when it actually produced a loss of $0.44, delivering no surprise.Over the last four quarters, the company has surpasse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share SCPH The Nasdaq Global Select Market Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

Exhibit 99.1 Pharmaceutica Powered by passion. Driven by patient care. scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and ...

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13th, at ...

BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the third quarter 2024 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 ( ...

scPharmaceuticals, Inc. (SCPH) closed the last trading session at $5.06, gaining 12.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.83 indicates a 291.9% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $2.99. While the lowest estimate of $16 indicates a 216.2% increase from the current price level, the most optimistic a ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes - CFO Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the scPharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. A brief question-and-answer session wi ...